Matching articles for "zanamivir"
Influenza Vaccine for 2024-2025
The Medical Letter on Drugs and Therapeutics • September 16, 2024; (Issue 1711)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2024-2025 season...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2024-2025 season are
listed in Table 2.
Antiviral Drugs for Influenza for 2023-2024
The Medical Letter on Drugs and Therapeutics • November 13, 2023; (Issue 1689)
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can
occur, especially in patients at increased risk for
influenza complications (see Table 1). Antiviral...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can
occur, especially in patients at increased risk for
influenza complications (see Table 1). Antiviral drugs
recommended for treatment and chemoprophylaxis
of influenza for the 2023-2024 season are listed in
Table 2. Updated information on influenza activity
and antiviral resistance is available from the CDC at
www.cdc.gov/flu.
Comparison Chart: Antiviral Drugs for Influenza for 2023-2024 (online only)
The Medical Letter on Drugs and Therapeutics • November 13, 2023; (Issue 1689)
...
View the Comparison Chart: Antiviral Drugs for Influenza for 2023-2024
Influenza Vaccine for 2023-2024
The Medical Letter on Drugs and Therapeutics • October 16, 2023; (Issue 1687)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024 season
are listed in Table 2.
Influenza Vaccine for 2023-2024
The Medical Letter on Drugs and Therapeutics • October 16, 2023; (Issue 1687)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024 season
are listed in Table 2.
Antiviral Drugs for Influenza for 2022-2023
The Medical Letter on Drugs and Therapeutics • November 28, 2022; (Issue 1664)
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory
failure, and death can occur, especially in patients
at increased risk for influenza complications (see
Table...
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory
failure, and death can occur, especially in patients
at increased risk for influenza complications (see
Table 1). Antiviral drugs recommended for treatment
and chemoprophylaxis of influenza this season are
listed in Table 2. Updated information on influenza
activity and antiviral resistance is available from the
CDC at www.cdc.gov/flu. None of the drugs that are
FDA-approved for treatment of influenza have clinically
relevant antiviral activity against SARS-CoV-2.
Comparison Chart: Antiviral Drugs for Influenza for 2022-2023 (online only)
The Medical Letter on Drugs and Therapeutics • November 28, 2022; (Issue 1664)
...
View the Comparison Chart: Antiviral Drugs for Influenza for 2022-2023
Influenza Vaccine for 2022-2023
The Medical Letter on Drugs and Therapeutics • October 3, 2022; (Issue 1660)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2022-2023...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2022-2023 season
are listed in Table 2.
Antiviral Drugs for Influenza for 2021-2022
The Medical Letter on Drugs and Therapeutics • January 10, 2022; (Issue 1641)
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory
failure, and death can occur, especially in patients
at higher risk for complications (see Table 1).
Antiviral...
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory
failure, and death can occur, especially in patients
at higher risk for complications (see Table 1).
Antiviral drugs recommended for treatment and
chemoprophylaxis of influenza this season are listed
in Table 2. Updated information on influenza activity
and antiviral resistance is available from the CDC at
www.cdc.gov/flu.
Comparison Chart: Antiviral Drugs for Influenza for 2021-2022 (online only)
The Medical Letter on Drugs and Therapeutics • January 10, 2022; (Issue 1641)
...
View the Comparison Chart: Antiviral Drugs for Influenza for 2021-2022
Influenza Vaccine for 2021-2022
The Medical Letter on Drugs and Therapeutics • October 4, 2021; (Issue 1634)
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication.1 Available influenza vaccines for the
2021-2022 season are listed in Table...
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication.1 Available influenza vaccines for the
2021-2022 season are listed in Table 2.
Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
The Medical Letter on Drugs and Therapeutics • January 11, 2021; (Issue 1615)
The oral polymerase acidic endonuclease inhibitor
baloxavir marboxil (Xofluza — Genentech) is now FDAapproved
for post-exposure prophylaxis of influenza
in patients ≥12 years old. Baloxavir was approved...
The oral polymerase acidic endonuclease inhibitor
baloxavir marboxil (Xofluza — Genentech) is now FDAapproved
for post-exposure prophylaxis of influenza
in patients ≥12 years old. Baloxavir was approved for
treatment of acute uncomplicated influenza in patients
≥12 years old in 2018.1 Two neuraminidase inhibitors
are FDA-approved for prophylaxis of influenza:
oseltamivir (Tamiflu, and generics) in patients ≥1 year
old, and zanamivir (Relenza) in patients ≥5 years old.2
Unlike oseltamivir and zanamivir, baloxavir is not FDA-approved
for pre-exposure prophylaxis of influenza
during institutional or community outbreaks.
Antiviral Drugs for Influenza for 2020-2021
The Medical Letter on Drugs and Therapeutics • November 2, 2020; (Issue 1610)
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory failure,
and death can occur, especially in patients at increased
risk for influenza complications (see Table...
Influenza is generally a self-limited illness, but
complications such as pneumonia, respiratory failure,
and death can occur, especially in patients at increased
risk for influenza complications (see Table 1).
Antiviral drugs recommended for treatment and
chemoprophylaxis of influenza this season are listed
in Table 2. Updated information on influenza activity
and antiviral resistance is available from the CDC at
www.cdc.gov/flu.
Comparison Chart: Antiviral Drugs for Influenza (online only)
The Medical Letter on Drugs and Therapeutics • November 2, 2020; (Issue 1610)
...
View the Comparison Chart: Antiviral Drugs for Influenza
Influenza Vaccine for 2020-2021
The Medical Letter on Drugs and Therapeutics • September 21, 2020; (Issue 1607)
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication. Vaccination of all eligible persons can
reduce the prevalence of influenza illness...
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication. Vaccination of all eligible persons can
reduce the prevalence of influenza illness and symptoms
that might be confused with those of COVID-19.
Available vaccines and recommendations for specific
patient populations for the 2020-2021 season are listed
in Tables 2 and 3. Lower rates of influenza illness have
been observed this season in the Southern Hemisphere,
probably because of masking, social distancing, school
closures, and travel restrictions.
Drugs Past Their Expiration Date
The Medical Letter on Drugs and Therapeutics • July 27, 2020; (Issue 1603)
Healthcare providers are often asked if drugs can
be used past their expiration date. Because of legal
restrictions and liability concerns, manufacturers do
not sanction such use and usually do not...
Healthcare providers are often asked if drugs can
be used past their expiration date. Because of legal
restrictions and liability concerns, manufacturers do
not sanction such use and usually do not comment
on the safety or effectiveness of their products beyond
the date on the label. Since our last article on this
subject, more data have become available.
Antiviral Drugs for Influenza
The Medical Letter on Drugs and Therapeutics • January 13, 2020; (Issue 1589)
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can occur.
FDA-approved antiviral drugs for influenza are listed
in Table 2. The neuraminidase inhibitors...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can occur.
FDA-approved antiviral drugs for influenza are listed
in Table 2. The neuraminidase inhibitors oseltamivir
(Tamiflu, and generics), which is taken orally, and
zanamivir (Relenza), which is inhaled, are approved
for prophylaxis and treatment of acute uncomplicated
influenza. The IV neuraminidase inhibitor peramivir
(Rapivab) and the oral polymerase acidic (PA)
endonuclease inhibitor baloxavir marboxil (Xofluza)
are approved only for treatment. All of these drugs
are active against both influenza A and influenza B
viruses. Updated information on influenza activity
and antiviral resistance is available from the CDC at
www.cdc.gov/flu.
Expanded Table: Antiviral Drugs for Influenza (online only)
The Medical Letter on Drugs and Therapeutics • January 13, 2020; (Issue 1589)
...
View the Expanded Table: Antiviral Drugs for Influenza
Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza
The Medical Letter on Drugs and Therapeutics • January 14, 2019; (Issue 1563)
Antiviral drugs can be used for treatment and
prophylaxis of seasonal influenza (see Table 1).
Frequently updated information on influenza activity,
influenza testing, and antiviral resistance is...
Antiviral drugs can be used for treatment and
prophylaxis of seasonal influenza (see Table 1).
Frequently updated information on influenza activity,
influenza testing, and antiviral resistance is available
from the CDC at www.cdc.gov/flu.
Expanded Table: Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza 2018-2019 (online only)
The Medical Letter on Drugs and Therapeutics • January 14, 2019; (Issue 1563)
...
View the Expanded Table: Antiviral Drugs for Seasonal Influenza
Baloxavir Marboxil (Xofluza) for Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • December 3, 2018; (Issue 1561)
The FDA has approved baloxavir marboxil (Xofluza –
Shionogi/Genentech), the first polymerase acidic (PA)
endonuclease inhibitor, for single-dose, oral treatment
of acute uncomplicated influenza in patients...
The FDA has approved baloxavir marboxil (Xofluza –
Shionogi/Genentech), the first polymerase acidic (PA)
endonuclease inhibitor, for single-dose, oral treatment
of acute uncomplicated influenza in patients ≥12 years
old. Baloxavir is the first drug with a new mechanism
of action to be approved for treatment of influenza in
almost 20 years.
Antiviral Drugs for Seasonal Influenza 2017-2018
The Medical Letter on Drugs and Therapeutics • January 1, 2018; (Issue 1537)
Antiviral drugs can be used for treatment and prophylaxis
of influenza. Frequently updated information on
influenza activity, testing for influenza, and antiviral
resistance is available from the CDC at...
Antiviral drugs can be used for treatment and prophylaxis
of influenza. Frequently updated information on
influenza activity, testing for influenza, and antiviral
resistance is available from the CDC at www.cdc.gov/flu.
Antiviral Drugs for Seasonal Influenza 2016-2017
The Medical Letter on Drugs and Therapeutics • January 2, 2017; (Issue 1511)
Antiviral drugs can be used for prophylaxis and treatment
of influenza. Frequently updated information on influenza
activity, testing for influenza, and antiviral resistance is
available from the CDC at...
Antiviral drugs can be used for prophylaxis and treatment
of influenza. Frequently updated information on influenza
activity, testing for influenza, and antiviral resistance is
available from the CDC at www.cdc.gov/flu.
Antiviral Drugs for Seasonal Influenza 2015-2016
The Medical Letter on Drugs and Therapeutics • December 21, 2015; (Issue 1484)
Antiviral drugs can be used for treatment of influenza
and as an adjunct to influenza vaccination1 for
prophylaxis. Frequently updated information on
influenza activity and antiviral resistance is...
Antiviral drugs can be used for treatment of influenza
and as an adjunct to influenza vaccination1 for
prophylaxis. Frequently updated information on
influenza activity and antiviral resistance is available
from the CDC at www.cdc.gov/flu.
Peramivir (Rapivab): An IV Neuraminidase Inhibitor for Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • February 2, 2015; (Issue 1461)
The FDA has approved peramivir (Rapivab – BioCryst),
an IV neuraminidase inhibitor administered as a single
dose, for treatment of acute uncomplicated influenza in
patients ≥18 years old who have had...
The FDA has approved peramivir (Rapivab – BioCryst),
an IV neuraminidase inhibitor administered as a single
dose, for treatment of acute uncomplicated influenza in
patients ≥18 years old who have had symptoms for no
more than 2 days. Peramivir was available temporarily
in the US during the 2009-2010 influenza season
under an emergency use authorization for treatment of
hospitalized patients. It has been available in some Asian
countries since 2010. Peramivir is the third neuraminidase
inhibitor to be approved in the US. Oseltamivir
(Tamiflu), which is taken orally, and zanamivir (Relenza),
which is inhaled, are approved for prophylaxis and
treatment of influenza in children and adults.
In Brief: Concerns about Oseltamivir (Tamiflu)
The Medical Letter on Drugs and Therapeutics • January 19, 2015; (Issue 1460)
Some readers of our article on Antiviral Drugs for Seasonal Influenza have expressed concerns regarding our recommendation for use of the oral neuraminidase inhibitor oseltamivir (Tamiflu) to treat high-risk...
Some readers of our article on Antiviral Drugs for Seasonal Influenza have expressed concerns regarding our recommendation for use of the oral neuraminidase inhibitor oseltamivir (Tamiflu) to treat high-risk patients with confirmed or suspected influenza illness, citing the British Medical Journal and The Cochrane Collaboration, which have contended that there is no acceptable evidence that the drug prevents complications or hospitalizations and have questioned the completeness of the results of controlled trials conducted by the manufacturer (Roche).
In Brief: Influenza in 2015
The Medical Letter on Drugs and Therapeutics • January 5, 2015; (Issue 1459)
The CDC has announced that the most common influenza viruses circulating now are influenza A H3N2, which tend to cause more severe disease, and that about half of these viruses are antigenically different from...
The CDC has announced that the most common influenza viruses circulating now are influenza A H3N2, which tend to cause more severe disease, and that about half of these viruses are antigenically different from the H3N2 strain in this year’s flu vaccine.1 Vaccination may still have a protective effect, even against drifted variants, and patients who have not received this year’s vaccine2 should be encouraged to do so.
Prompt treatment of confirmed or suspected influenza illness with antiviral drugs is recommended for hospitalized patients, for those with severe, complicated, or progressive illness, and for persons at high risk of complications: children <2 years old, adults ≥65 years old, women who are pregnant or ≤2 weeks postpartum, persons <19 years old receiving long-term aspirin therapy, morbidly obese patients (BMI ≥40), persons of American Indian/Alaskan Native heritage, residents of nursing homes or chronic-care facilities, and patients who are immunosuppressed or have chronic diseases such as asthma, diabetes, or heart, lung, or kidney disease.
The neuraminidase inhibitors oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), which is inhaled, taken within 48 hours after the onset of illness can decrease the duration of fever and symptoms in uncomplicated influenza and may reduce the incidence of pneumonia and death in high-risk patients.3 All of the influenza viruses tested to date for resistance to neuraminidase inhibitors this season have been susceptible to both oseltamivir and zanamivir.1
Download complete U.S. English article
Prompt treatment of confirmed or suspected influenza illness with antiviral drugs is recommended for hospitalized patients, for those with severe, complicated, or progressive illness, and for persons at high risk of complications: children <2 years old, adults ≥65 years old, women who are pregnant or ≤2 weeks postpartum, persons <19 years old receiving long-term aspirin therapy, morbidly obese patients (BMI ≥40), persons of American Indian/Alaskan Native heritage, residents of nursing homes or chronic-care facilities, and patients who are immunosuppressed or have chronic diseases such as asthma, diabetes, or heart, lung, or kidney disease.
The neuraminidase inhibitors oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), which is inhaled, taken within 48 hours after the onset of illness can decrease the duration of fever and symptoms in uncomplicated influenza and may reduce the incidence of pneumonia and death in high-risk patients.3 All of the influenza viruses tested to date for resistance to neuraminidase inhibitors this season have been susceptible to both oseltamivir and zanamivir.1
- CDC health advisory regarding the potential for circulation of drifted influenza A (H3N2) viruses. Available at http://emergency.cdc.gov. Accessed December 18, 2014.
- Influenza vaccine for 2014-2015. Med Lett Drugs Ther 2014; 56:97.
- Antiviral drugs for seasonal influenza 2014-2015. Med Lett Drugs Ther 2014; 56:121.
Download complete U.S. English article
Antiviral Drugs for Seasonal Influenza 2014-2015
The Medical Letter on Drugs and Therapeutics • December 8, 2014; (Issue 1457)
Antiviral drugs can be used for treatment of influenza
and as an adjunct to influenza vaccination for prophylaxis.
Frequently updated information on influenza
activity and antiviral resistance is available...
Antiviral drugs can be used for treatment of influenza
and as an adjunct to influenza vaccination for prophylaxis.
Frequently updated information on influenza
activity and antiviral resistance is available from the
CDC at www.cdc.gov/flu.
Antiviral Drugs for Influenza 2013-2014
The Medical Letter on Drugs and Therapeutics • January 20, 2014; (Issue 1434)
Antiviral drugs can be used for treatment of influenza and
as an adjunct to influenza vaccination for prophylaxis. Frequently
updated information on antiviral resistance is available
at...
Antiviral drugs can be used for treatment of influenza and
as an adjunct to influenza vaccination for prophylaxis. Frequently
updated information on antiviral resistance is available
at www.cdc.gov.
Antiviral Drugs
The Medical Letter on Drugs and Therapeutics • March 1, 2013; (Issue 127)
The drugs of choice for treatment of viral infections
(other than HIV) and their dosages are listed in Tables
1-6 on the pages that follow. Some of the indications
and dosages recommended here have not...
The drugs of choice for treatment of viral infections
(other than HIV) and their dosages are listed in Tables
1-6 on the pages that follow. Some of the indications
and dosages recommended here have not been
approved by the FDA. Vaccines used for the prevention
of viral infections are discussed elsewhere.
Antiviral Drugs for Influenza 2012-2013
The Medical Letter on Drugs and Therapeutics • December 10, 2012; (Issue 1405)
Antiviral drugs can be used as an adjunct to
vaccination for prophylaxis and treatment of influenza.
In recent years, the susceptibility of circulating influenza
virus strains has evolved rapidly and...
Antiviral drugs can be used as an adjunct to
vaccination for prophylaxis and treatment of influenza.
In recent years, the susceptibility of circulating influenza
virus strains has evolved rapidly and treatment recommendations
have changed during the influenza season.
Frequently updated information on antiviral resistance is
available at www.cdc.gov/flu/professionals/antivirals.
Antiviral Drugs for Influenza
The Medical Letter on Drugs and Therapeutics • January 10, 2011; (Issue 1355)
Antiviral drugs can be used for treatment of patients with influenza and for prophylaxis when exposure to the disease occurs before or less than 2 weeks after vaccination. They can also be used to control...
Antiviral drugs can be used for treatment of patients with influenza and for prophylaxis when exposure to the disease occurs before or less than 2 weeks after vaccination. They can also be used to control institutional outbreaks of influenza. In recent years, the susceptibility of circulating influenza strains has evolved rapidly and treatment recommendations have changed during the influenza season. The CDC influenza web site provides frequently updated information on antiviral resistance (www.cdc.gov/flu)
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • October 1, 2010; (Issue 98)
The drugs of choice for treatment of non-HIV viral
infections and their dosages are listed in Tables 1-6 on
the pages that follow. Some of the indications and
dosages recommended here have not been...
The drugs of choice for treatment of non-HIV viral
infections and their dosages are listed in Tables 1-6 on
the pages that follow. Some of the indications and
dosages recommended here have not been approved
by the FDA. Vaccines used for the prevention of viral
infections are discussed in another issue of Treatment
Guidelines.
Antiviral Drugs for Influenza
The Medical Letter on Drugs and Therapeutics • November 16, 2009; (Issue 1325)
Currently circulating influenza virus is almost universally pandemic 2009 influenza A H1N1, but seasonal influenza strains could also appear soon. Antiviral drugs are an important adjunct to influenza...
Currently circulating influenza virus is almost universally pandemic 2009 influenza A H1N1, but seasonal influenza strains could also appear soon. Antiviral drugs are an important adjunct to influenza vaccination for treatment and chemoprophylaxis of both pandemic and seasonal influenza. They may, however, interfere with the efficacy of FluMist, the live-attenuated intranasal vaccine, if they are administered within 48 hours before or <2 weeks after FluMist administration. Inactivated vaccines are not affected by antiviral drug therapy.
More Resistance to Oseltamivir (Tamiflu)
The Medical Letter on Drugs and Therapeutics • January 26, 2009; (Issue 1304)
Since publication of our recent article on antiviral drugs for influenza, increased levels of resistance to oseltamivir (Tamiflu) have been detected in influenza A H1N1...
Since publication of our recent article on antiviral drugs for influenza, increased levels of resistance to oseltamivir (Tamiflu) have been detected in influenza A H1N1 strains.
Antiviral Drugs for Influenza
The Medical Letter on Drugs and Therapeutics • December 15, 2008; (Issue 1301)
Antiviral drugs are an important adjunct to influenza vaccination and can be used for treatment of patients with influenza within 2 days of the onset of illness and for chemoprophylaxis of influenza exposures...
Antiviral drugs are an important adjunct to influenza vaccination and can be used for treatment of patients with influenza within 2 days of the onset of illness and for chemoprophylaxis of influenza exposures that occur before or less than 2 weeks after vaccination. Patients who are immunocompromised or immunosuppressed, have pulmonary disease, are elderly or are healthcare workers may also be appropriate candidates for chemoprophylaxis.
Antiviral Drugs for Influenza
The Medical Letter on Drugs and Therapeutics • October 22, 2007; (Issue 1272)
Antiviral drugs can be used for treatment of patients with influenza and for prophylaxis of influenza exposures that occur before or less than 2 weeks after vaccination. They can also be used to control...
Antiviral drugs can be used for treatment of patients with influenza and for prophylaxis of influenza exposures that occur before or less than 2 weeks after vaccination. They can also be used to control institutional influenza outbreaks and for prophylaxis in years when circulating strains differ from those included in the vaccine.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • July 1, 2007; (Issue 59)
The drugs of choice for treatment of non-HIV viral infections with their dosages and cost are listed in Tables 1-6. Some of the indications and dosages recommended here have not been approved by the FDA....
The drugs of choice for treatment of non-HIV viral infections with their dosages and cost are listed in Tables 1-6. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used in the prevention of viral infections are discussed in the "Adult Immunization" issue of Treatment Guidelines.
Antiviral Drugs for Prophylaxis and Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • October 23, 2006; (Issue 1246)
Antiviral drugs can be used to control institutional influenza outbreaks and for prophylaxis of influenza exposures that occur before or less than 2 weeks after vaccination with inactivated vaccine, or in years...
Antiviral drugs can be used to control institutional influenza outbreaks and for prophylaxis of influenza exposures that occur before or less than 2 weeks after vaccination with inactivated vaccine, or in years when circulating strains differ from those included in the vaccine. They can also be used for early treatment of patients with influenza.
Antiviral Drugs for Prophylaxis and Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • November 21, 2005; (Issue 1222)
Antiviral prophylaxis is indicated for influenza exposures that occur before (or less than 2 weeks after) vaccination with inactivated vaccine, or in years when circulating strains differ from those included in...
Antiviral prophylaxis is indicated for influenza exposures that occur before (or less than 2 weeks after) vaccination with inactivated vaccine, or in years when circulating strains differ from those included in the vaccine. Antiviral drugs can also be used for treatment of patients who develop symptoms of influenza, regardless of vaccination status.
Please see Update: Influenza Resistance to Amantadine and Rimantadine
Please see Update: Influenza Resistance to Amantadine and Rimantadine
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • April 1, 2005; (Issue 32)
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the tables that begin on page 24. Some of the indications and dosages recommended here have not been approved by the...
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the tables that begin on page 24. Some of the indications and dosages recommended here have not been approved by the FDA.
Antiviral Drugs for Prophylaxis and Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • October 25, 2004; (Issue 1194)
Due to the unanticipated shortage in the US supply of inactivated influenza vaccine, many persons who normally would have received the vaccine will be unable to get it this year. Antiviral drugs can be used...
Due to the unanticipated shortage in the US supply of inactivated influenza vaccine, many persons who normally would have received the vaccine will be unable to get it this year. Antiviral drugs can be used for prophylaxis of unvaccinated persons who are exposed to influenza, and for treatment of both vaccinated and unvaccinated patients who develop symptoms of the disease.
Influenza Prevention 2003-2004
The Medical Letter on Drugs and Therapeutics • September 29, 2003; (Issue 1166)
Unlike the last few years there is no early-season shortage of influenza vaccine. Immunization programs for all recommended individuals can proceed. There are 2 new influenza vaccine formulations available...
Unlike the last few years there is no early-season shortage of influenza vaccine. Immunization programs for all recommended individuals can proceed. There are 2 new influenza vaccine formulations available this year, FluMist, an intranasal vaccine and Fluzone, a pediatric formulation. Timing, indications, adverse effects, dosage and cost of the vaccines is discussed. The drugs that can be used for prophylaxis of influenza are also reviewed.
Drugs for Pneumonia
The Medical Letter on Drugs and Therapeutics • September 1, 2003; (Issue 13)
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid...
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.
FluMist: An Intranasal Live Influenza Vaccine
The Medical Letter on Drugs and Therapeutics • August 19, 2003; (Issue 1163)
FluMist (MedImmune), the first live-attenuated and first intranasally administered influenza vaccine, has been approved by the FDA to prevent influenza in healthy people 5-49 years old. Given as a nasal spray,...
FluMist (MedImmune), the first live-attenuated and first intranasally administered influenza vaccine, has been approved by the FDA to prevent influenza in healthy people 5-49 years old. Given as a nasal spray, it stimulates immunity by viral replication in the upper respiratory tract. This vaccine apparently will be advertised directly to the public as a "needle-free" alternative to intramuscular influenza vaccine.
Influenza Prevention 2002-2003
The Medical Letter on Drugs and Therapeutics • September 2, 2002; (Issue 1138)
Influenza vaccine for the 2002-2003 season will include last year's A strains, A/New Caledonia/20/99 (H1N1)-like and A/Moscow/10/99 (H3N2)-like, and a new B strain, B/Hong-Kong/330/01-like (MMWR Morb Mortal...
Influenza vaccine for the 2002-2003 season will include last year's A strains, A/New Caledonia/20/99 (H1N1)-like and A/Moscow/10/99 (H3N2)-like, and a new B strain, B/Hong-Kong/330/01-like (MMWR Morb Mortal Wkly Rep 2002; 51:503).
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • February 4, 2002; (Issue 1123)
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table that begins on the next page. Since the last Medical Letter issue on this subject, some new drugs and some...
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table that begins on the next page. Since the last Medical Letter issue on this subject, some new drugs and some new recommendations for old drugs have been added.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • December 3, 1999; (Issue 1067)
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the [article's]...
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the [article's] table.
Two Neuraminidase Inhibitors for Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • October 8, 1999; (Issue 1063)
Zanamivir, a neuraminidase inhibitor taken by inhalation, has been approved by the FDA for treatment of influenza. Oseltamivir phosphate, an oral neuraminidase inhibitor, will probably be approved...
Zanamivir, a neuraminidase inhibitor taken by inhalation, has been approved by the FDA for treatment of influenza. Oseltamivir phosphate, an oral neuraminidase inhibitor, will probably be approved soon.